Mechanisms of Resistance to Chemotherapy in Breast Cancer and Possible Targets in Drug Delivery Systems

Autor(es)

Lainetti, Patricia de Faria ^[1] ; Leis-Filho, Antonio Fernando ^[1] ; Laufer-Amorim, Renee ^[2] ; Battazza, Alexandre ^[3] ; Fonseca-Alves, Carlos Eduardo ^{[1, 4]}

Afiliação do(s) autor(es)

^[1] Sao Paulo State Univ UNESP, Dept Vet Surg & Anim Reprod, BR-18618681 Botucatu, SP - Brazil

^[2] Sao Paulo State Univ UNESP, Dept Vet Clin, BR-18618681 Botucatu, SP - Brazil

^[3] Sao Paulo State Univ UNESP, Dept Pathol, Botucatu Med Sch, BR-18618681 Botucatu, SP - Brazil

^[4] Paulista Univ UNIP, Inst Hlth Sci, BR-17048290 Bauru, SP - Brazil

• Tipo de documento: Artigo de Revisão
• Fonte: PHARMACEUTICS; v. 12, n. 12 DEC 2020.
• Citações Web of Science: 0

Resumo

Breast cancer (BC) is one of the most important cancers worldwide, and usually, chemotherapy can be used in an integrative approach. Usually, chemotherapy treatment is performed in association with surgery, radiation or hormone therapy, providing an increased outcome to patients. However, tumors can develop resistance to different drugs, progressing for a more aggressive phenotype. In this scenario, the use of nanocarriers could help to defeat tumor cell resistance, providing a new therapeutic perspective for patients. Thus, this systematic review aims to bring the molecular mechanisms involved in BC chemoresistance and extract from the previous literature information regarding the use of nanoparticles as potential treatment for chemoresistant breast cancer. (AU)

• Processo FAPESP: 19/24001-2 - Estudo molecular para identificação de novos fatores preditivos em células mamárias humanas e caninas quimioresistentes
• Beneficiário: Patrícia de Faria Lainetti
• Linha de fomento: Bolsas no Brasil - Doutorado
• Processo FAPESP: 19/24079-1 - Efeito Antitumoral do Látex Synadenium Grantii Hook F. em Modelos Pré-clínicos de Carcinomas Mamários
• Beneficiário: Carlos Eduardo Fonseca Alves
• Linha de fomento: Auxílio à Pesquisa - Regular